Dark
Light
Today: May 13, 2024
January 5, 2024
1 min read

“Xcellerant Ventures Boosts CRISPR QC’s Funding in Series A Round”

TLDR:

  • Biotechnology startup CRISPR QC has secured funding from Xcellerant Ventures in a series A funding round. The amount of funding has not been disclosed.
  • The funding will be used to further develop the company’s CRISPR Analytics Platform, which provides comprehensive measurements and analysis of CRISPR activity.
  • CRISPR QC’s platform is built on its proprietary CRISPR-Chip technology, enabling direct and real-time measurement of CRISPR activity.
  • The company plans to open a satellite office in Sedona, Arizona, as it continues to grow.

The San Diego-based biotechnology startup, CRISPR QC, has secured funding from Xcellerant Ventures in its ongoing series A funding round. The amount of funding has not been disclosed. The backing from Xcellerant Ventures will be used to fund further developments in CRISPR QC’s CRISPR Analytics Platform. The platform leverages the company’s proprietary CRISPR-Chip technology to provide comprehensive measurements and analysis of CRISPR activity. This enables scientists and researchers to optimize gene editing outcomes and ensure high levels of quality control.

CRISPR QC’s CRISPR Analytics Platform has the capability for direct, real-time measurement of CRISPR activity, thanks to the company’s proprietary CRISPR-Chip technology. This technology allows for efficient and accurate analysis of gene editing outcomes, providing valuable insights for researchers and scientists.

As the company expands, CRISPR QC is planning to open a satellite office in Sedona, Arizona. This expansion demonstrates the company’s growth and commitment to its mission of providing advanced tools for gene editing research.

In conclusion, CRISPR QC’s successful funding round with Xcellerant Ventures will enable the further development of its CRISPR Analytics Platform. The proprietary CRISPR-Chip technology sets the company apart, allowing for direct and real-time measurement of CRISPR activity. This funding will support the company’s growth and expansion, including the opening of a satellite office in Sedona, Arizona. Overall, CRISPR QC is poised to contribute to advancements in gene editing research and ensure high levels of quality control in the field.

Previous Story

“5 Game Over: The Failed Cleantech Startups of 2024”

Next Story

“2023: A Rollercoaster Ride for Venture Funding with 31% Decrease”

Latest from Blog

Go toTop